Geneva Capital Management LLC Sells 5,613 Shares of HealthEquity, Inc. (NASDAQ:HQY)

Geneva Capital Management LLC cut its position in shares of HealthEquity, Inc. (NASDAQ:HQY) by 0.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 870,735 shares of the company’s stock after selling 5,613 shares during the quarter. Geneva Capital Management LLC’s holdings in HealthEquity were worth $57,730,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. FMR LLC boosted its holdings in shares of HealthEquity by 19.1% in the 3rd quarter. FMR LLC now owns 5,648,992 shares of the company’s stock valued at $412,659,000 after buying an additional 907,743 shares during the last quarter. Mackenzie Financial Corp increased its stake in shares of HealthEquity by 58.2% during the 4th quarter. Mackenzie Financial Corp now owns 1,807,407 shares of the company’s stock worth $119,831,000 after purchasing an additional 664,979 shares during the last quarter. Invesco Ltd. lifted its stake in HealthEquity by 164.6% in the 3rd quarter. Invesco Ltd. now owns 484,043 shares of the company’s stock valued at $35,359,000 after purchasing an additional 301,078 shares during the last quarter. Clearbridge Investments LLC grew its holdings in HealthEquity by 12.1% during the third quarter. Clearbridge Investments LLC now owns 2,204,675 shares of the company’s stock worth $161,051,000 after purchasing an additional 238,116 shares during the period. Finally, Eagle Asset Management Inc. acquired a new position in HealthEquity during the third quarter worth approximately $15,581,000. 99.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on HQY shares. Royal Bank of Canada lifted their target price on HealthEquity from $90.00 to $92.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 20th. Barclays lifted their price objective on shares of HealthEquity from $84.00 to $104.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Barrington Research reissued an “outperform” rating and issued a $100.00 price objective on shares of HealthEquity in a research report on Friday, March 22nd. JPMorgan Chase & Co. upped their price target on shares of HealthEquity from $86.00 to $108.00 and gave the company an “overweight” rating in a research note on Tuesday, April 2nd. Finally, KeyCorp increased their price target on shares of HealthEquity from $85.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, March 22nd. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, HealthEquity presently has an average rating of “Moderate Buy” and an average target price of $96.17.

HealthEquity Price Performance

HealthEquity stock traded down $0.56 during mid-day trading on Thursday, reaching $77.45. 794,378 shares of the company were exchanged, compared to its average volume of 595,660. The firm has a market cap of $6.65 billion, a PE ratio of 121.63, a PEG ratio of 1.28 and a beta of 0.55. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.76 and a quick ratio of 4.76. The company has a fifty day simple moving average of $80.56 and a 200-day simple moving average of $74.75. HealthEquity, Inc. has a 12 month low of $53.58 and a 12 month high of $84.49.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings results on Tuesday, March 19th. The company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.08. HealthEquity had a return on equity of 6.91% and a net margin of 5.57%. The business had revenue of $262.39 million during the quarter, compared to the consensus estimate of $258.56 million. As a group, equities research analysts expect that HealthEquity, Inc. will post 2.12 earnings per share for the current fiscal year.

Insider Transactions at HealthEquity

In other news, EVP Delano Ladd sold 2,558 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $82.59, for a total transaction of $211,265.22. Following the completion of the transaction, the executive vice president now owns 47,438 shares of the company’s stock, valued at approximately $3,917,904.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, CEO Jon Kessler sold 33,765 shares of the stock in a transaction on Friday, March 22nd. The stock was sold at an average price of $79.81, for a total value of $2,694,784.65. Following the completion of the transaction, the chief executive officer now directly owns 126,635 shares in the company, valued at approximately $10,106,739.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Delano Ladd sold 2,558 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $82.59, for a total value of $211,265.22. Following the sale, the executive vice president now owns 47,438 shares in the company, valued at approximately $3,917,904.42. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,322 shares of company stock valued at $5,682,895. Company insiders own 2.70% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.